These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 16191171

  • 21. Stability of parathyroid hormone ex vivo in haemodialysis patients.
    Teal TK, Reed M, Stevens PE, Lamb EJ.
    Ann Clin Biochem; 2003 Mar; 40(Pt 2):191-3. PubMed ID: 12662412
    [Abstract] [Full Text] [Related]

  • 22. Bone metabolism and disease--K/DOQI impact on nurses and dietitians.
    Knapp S.
    Nephrol Nurs J; 2004 Mar; 31(3):333-5. PubMed ID: 15303430
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Several PTH assay and the problem].
    Kato H, Mitarai T.
    Clin Calcium; 2007 May; 17(5):745-51. PubMed ID: 17471005
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Parathormone and chronic kidney disease].
    Bacchetta J, Jolivot A, Souberbielle JC, Charrié A, Guebre F, Chauvet C, Fouque D.
    Nephrol Ther; 2007 Jul; 3(4):133-8. PubMed ID: 17658439
    [Abstract] [Full Text] [Related]

  • 32. The influence of growth hormone treatment on bone metabolism in dialysis patients.
    Sieniawska M, Pañczyk-Tomaszewska M, Ziólkowska H.
    Br J Clin Pract Suppl; 1996 Aug; 85():61-3. PubMed ID: 8995036
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Chronic renal failure complications and management in kidney transplanted and nontransplanted patients.
    Kaysi S, Hadj Abdelkader M, Aniort J, Garrouste C, Philipponnet C, Deteix P, Heng AE.
    Transplant Proc; 2012 Dec; 44(10):2997-3000. PubMed ID: 23195013
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Are the K/DOQI objectives for bone mineral alterations in stage 3-5 chronic kidney disease patients unreachable or inadequate?
    Fernández E.
    Nefrologia; 2013 Jan 18; 33(1):1-6. PubMed ID: 23364622
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.